CT and gonorrhea testing market seen topping $3.47B by 2030

The global market for Chlamydia trachomatis and Neisseria gonorrhoeae testing is projected to grow from $2.19 billion in 2025 to $2.43 billion in 2026, with continued expansion to $3.47 billion by 2030. Growth is being driven by broader STI screening, faster molecular diagnostics and rising demand for point-of-care and home-testing options.

Why it matters: - CT and NG testing sits at the center of STI screening and treatment, with earlier diagnosis helping reduce complications and transmission. - The market’s growth signals rising demand for faster, more accessible sexual health diagnostics across clinical and at-home settings.

What happened: - The Business Research Company released a 2026 market report on the global Chlamydia trachomatis and Neisseria gonorrhoeae testing market. - The market is expected to grow from $2.19 billion in 2025 to $2.43 billion in 2026, a 10.9% CAGR. - The report forecasts the market will reach $3.47 billion by 2030, at a 9.3% CAGR. - North America was the largest regional market in 2025.

The details: - The report links recent growth to expanded screening among sexually active people, more laboratory infrastructure, and wider use of nucleic acid amplification tests and PCR. - The report also points to growing awareness of co-infections and a larger number of diagnostic laboratories worldwide. - Looking ahead, the market is expected to benefit from investment in decentralized and point-of-care testing. - Home-based diagnostic kits are gaining acceptance. - Automated laboratory platforms are expanding. - Integrated CT/NG testing solutions are seeing stronger demand. - The report highlights adoption of multiplex STI panels, rapid point-of-care testing, self-testing kits, high-sensitivity molecular assays and laboratory automation as key trends. - Testing uses urine samples, genital swabs or blood tests to detect the bacteria and support timely treatment. - The report says testing is especially relevant for sexually active people with multiple partners or people who have unprotected sex.

Between the lines: - Rising STI prevalence is the core demand driver behind the market forecast. - Limited sex education, social stigma and barriers to healthcare access are adding pressure to testing needs. - The inclusion of HIV prevalence data underscores how broader infectious disease burden is reinforcing demand for comprehensive STI diagnostics. - The report said about 39.9 million people worldwide were living with HIV in 2023, based on October 2025 data from the Minority HIV/AIDS Fund.

What's next: - The report expects continued gains as healthcare providers prioritize early detection and treatment. - The company says future reporting will include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The report is available as a free sample and full version through the company's announcement and the full report.